Innoviva Inc  

(Public, NASDAQ:INVA)   Watch this stock  
Find more results for NASDAQ:THRX
+0.30 (2.40%)
After Hours: 12.80 -0.02 (-0.16%)
Apr 24, 5:37PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.70 - 13.06
52 week 8.67 - 14.55
Open 12.70
Vol / Avg. 1.21M/1.91M
Mkt cap 1.39B
P/E 29.08
Div/yield 0.25/7.80
EPS 0.44
Shares 108.44M
Beta 2.33
Inst. own 84%
Apr 27, 2017
Q1 2017 Innoviva Inc Earnings Call - 5:00PM EDT - Add to calendar
Apr 20, 2017
Innoviva Inc Annual Shareholders Meeting
Mar 7, 2017
Innoviva Inc at Cowen Health Care Conference - Webcast
Feb 9, 2017
Q4 2016 Innoviva Inc Earnings Call
Feb 9, 2017
Q4 2016 Innoviva Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 58.40% 44.57%
Operating margin 86.35% 81.60%
EBITD margin - 92.04%
Return on average assets 27.26% 15.11%
Return on average equity - -
Employees 14 -
CDP Score - -


2000 Sierra Point Pkwy Ste 500
BRISBANE, CA 94005-1830
United States - Map
+1-650-2389600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Officers and directors

William H. Waltrip Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Eric D'Esparbes Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Theodore J. Witek Jr. Senior Vice President, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Michael E. Faerm Senior Vice President and Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Michael W. Aguiar President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Barbara G. Duncan Independent Director
Bio & Compensation  - Reuters
Catherine J. Friedman Independent Director
Age: 55
Bio & Compensation  - Reuters
Patrick G. LePore Independent Director
Bio & Compensation  - Reuters
Paul A. Pepe Independent Director
Age: 57
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 64
Bio & Compensation  - Reuters